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Dendritic cells (DCs) are central players of immune responses; they become activated upon infection or inflammation and migrate
to lymph nodes, where they can initiate an antigen-specific immune response by activating naive T cells. Two major types of
naturally occurring DCs circulate in peripheral blood, namely, myeloid and plasmacytoid DCs (pDCs). Myeloid DCs (mDCs)
can be subdivided based on the expression of either CD1c or CD141. These human DC subsets differ in surface marker expression,
Toll-like receptor (TLR) repertoire, and transcriptional profile, suggesting functional differences between them. Here, we directly
compared the capacity of human blood mDCs and pDCs to activate and polarize CD4+ T cells. CD141+ mDCs show an overall
more mature phenotype over CD1c+ mDC and pDCs; they produce less IL-10 and more IL-12 than CD1c+ mDCs. Despite these
differences, all subsets can induce the production of IFN-𝛾 in naive CD4+ T cells. CD1c+ and CD141+ mDCs especially induce a
strong T helper 1 profile. Importantly, naive CD4+ T cells are not polarized towards regulatory T cells by any subset. These findings
further establish all three human blood DCs—despite their differences—as promising candidates for immunostimulatory effectors
in cancer immunotherapy.
1. Introduction
Dendritic cells (DCs) are professional antigen-presenting
cells that possess the unique capacity to activate and prime
naive CD4+ and CD8+ T cells [1].They form a heterogeneous
population consisting of specialized DC subsets that differ in
their surface marker expression, molecular phenotype, and
antigen-processing and antigen-presentation capacity [2–4].
In peripheral blood, at least two major types of DCs can be
distinguished, namely, myeloid DCs (mDCs) and plasmacy-
toid DCs (pDCs) [5, 6]. Myeloid DCs express high levels of
CD11c and can further be subdivided based on the differential
expression of either CD1c (blood dendritic cell antigen 1 =
BDCA1) or CD141 (BDCA3). Each DC subset has its own
repertoire of Toll-like receptors (TLRs), underlining their
functional specialization [3, 7]. Plasmacytoid DCs express
mainly TLR7 andTLR9. BothmDC subsets express TLR3 and
TLR8 among others, although expression levels of TLR3 are
much higher in CD141+mDCs [7]. Plasmacytoid DCs are key
effectors of innate immune responses due to their capacity to
produce large amounts of type I IFNs in response to bacterial
or viral infections; this production can also be induced by
TLR agonists such as R848 and oligodeoxynucleotides class
C (CpG) [8, 9]. Besides their role in the innate immune
system, pDCs also participate in priming T helper (Th) cells,
depending on the stimulus they receive (summarized in
[9]). Myeloid DCs, on the other hand, have the capacity to
produce the Th1 skewing cytokine interleukin- (IL-) 12. For
both pDCs and mDCs, it has been shown that they induce
proliferation in an allogeneic setting and that they can cross-
present exogenous antigens to prime CD8+ T cells [10–16].
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As a result of their unique capacity to orchestrate adaptive
immune responses, DCs are being exploited for cancer
immunotherapy. Recently, more advanced examination of
primary blood DCs has come within reach through the
availability of efficient isolation techniques. Primary DCs are
hypothesized to be stronger inducers of anticancer responses
than monocyte derived DCs in cell-based vaccination strate-
gies since they differentiate in vivo and require only short
ex vivo handling. The first clinical studies utilizing primary
blood DCs have recently been conducted by our group,
demonstrating the safety and efficacy of CD1c+ mDCs and
pDCs in cancer immunotherapy [17, 18].
In order for DC-based immunotherapy to elicit potent
antitumor T cell responses, the administered DCs need to
raise an immune-stimulatory rather than tolerogenic T cell
response [19]. Naive T cells will proliferate upon encounter
with antigen-presenting cells presenting their specific antigen
in the presence of costimulatory signals. The nature of cos-
timulation and cytokines from the DC will influence the
polarization of the T cells into different T helper phenotypes
such as Th1, Th2, and Th17 or regulatory T cells (Tregs). For
example, the presence of IL-12 promotes the induction of
Th1 cells, whereas IL-10 inhibits induction of Th1 cells and
promotes the differentiation of Tregs [20, 21]. In antiviral
responses, Th1 cells and antigen-specific cytotoxic CD8+ T
cells are elicited to eradicate cells infected by the virus. This
type of immune response is also highly desirable in antitumor
strategies, in which the aim is to eradicate tumor cells. Toll-
like receptor ligands such as polyinosinic:polycytidylic acid
(polyI:C), R848, and CpG have been shown to possess Th1
polarizing capacity when used as adjuvants or maturation
agents for DCs [22–26].
To be able to successfully manipulate T cell responses
for therapeutic strategies, a better understanding of the
functional specialization of human DC subsets is needed. In
this study, we compared the CD4+ T cell stimulatory and
polarizing capacity of human blood mDCs and pDCs side by
side—especially the capacity to induce Th1 responses upon
differential stimulation.
2. Material and Methods
2.1. Cells. Human blood DCs were isolated from buffy coats
(Sanquin) obtained from healthy volunteers after written
informed consent and according to institutional guidelines.
PBMCs were purified via Ficoll density gradient centrifuga-
tion (Lymphoprep by Axis-Shield). Monocytes were depleted
via plastic adherence.
DCs were isolated by fluorescence-activated cell sorting
(FACS). For this, lineage positive cells were depleted from
PBMCs either with Dynabeads Human DC enrichment
kit (Invitrogen by Life Technologies) or with anti-FITC
microbeads (Miltenyi Biotec) after incubation
with FITC-conjugated anti-Lin1 antibody cocktail
(CD3+CD14+CD16+CD19+CD20+CD56+) (BD Biosciences).
The remaining cells were labeled with FITC-conjugated anti-
Lin1 antibody cocktail (BD Biosciences), PE-Cy7-conjugated
anti-HLA-DR (BD Biosciences), BV421-conjugated anti-
CD1c (Biolegend), APC-conjugated anti-CD141 (Miltenyi
Biotec), and PE-conjugated anti-BDCA4 (Miltenyi Biotec).
Subsets were sorted to obtain CD1c+ mDCs, CD141+ mDCs,
or pDCs, respectively (purity 98–100%) (see Suppl. Fig. 1 in
Supplementary Material available online at http://dx.doi.org/
10.1155/2016/3605643). In some experiments, CD1c+ mDCs
were isolated from PBMCs with a CD1c+ DC isolation kit
(Miltenyi Biotec). CD141+ mDCs and pDCs were isolated
from PBLs by positive selection with anti-CD141 (CD141) and
anti-BDCA4 magnetic microbeads, respectively (Miltenyi
Biotec). Purity was assessed by flow cytometry (85–97%).
Naive CD4+ T cells were isolated from PBLs by depleting
CD4− cells with MACS MultiSort beads and additional use
of PE-conjugated anti-CD45RO (Dako) and anti-PE beads
(Miltenyi Biotec) for the depletion of CD45RO+ memory T
cells (purity > 95%).
All cells were cultured in X-VIVO 15 medium (Lonza)
supplemented with 2% human serum (Sigma-Aldrich). The
DCs were stimulated with the following TLR ligands:
4 𝜇g/mL R848 (Axxora), 2 𝜇g/mL polyI:C (Sigma) (Figures
1 and 2) or 20 𝜇g/mL polyI:C (Enzo Life Sciences) (Figures
3 and 4), 450U/mL GM-CSF (Cellgenix), or 5 𝜇g/mL CpG-
C (designated CpG throughout text; Enzo Life Sciences).
For the control condition of pDCs, the medium was supple-
mented with 10 ng/mL recombinant human IL-3 (Cellgenix)
to ensure pDC survival.
Cell sorting was performed on a BD Aria and flow
cytometry on a BD Calibur or BD Verse. The flow cytometry
data was analyzed by FlowJo software.
2.2. Phenotype andCytokine Production of TLRActivatedDCs.
TheDC subsets were incubated overnight at 37∘Cwith differ-
ent stimuli in triplicate (CD1c+ mDCs, pDCs) or in duplicate
(CD141+ mDCs). The next day, supernatants were taken and
cells were labeled with PE-conjugated anti-MHC class I and
FITC-conjugated anti-MHC class II (BD), PE-conjugated
anti-CD80 (BD Biosciences), and PE-conjugated anti-CD86
(BD Biosciences). Marker expression was determined by flow
cytometry (BD Calibur and FlowJo software). Supernatants
were analyzed for IL-10 (eBioscience) and IL-12p70 (M122
and M121B by Pierce Endogen, standard by BD Biosciences)
by standard sandwich ELISA. Depicted in Figure 2 is the
cytokine production by 50,000DCs in a volumeof 100𝜇L. For
CD141+ mDCs, in some instances fewer cells were cultured.
In all instances, cytokine production per cell was calculated.
2.3. T Cell Proliferation with Allogeneic Naive CD4+ T Cells.
CD1c+ mDCs, CD141+ mDCs, or pDCs (1 × 104 cells)
were incubated overnight at 37∘C with different stimuli in
triplicate. The next day, allogeneic naive CD4+ T cells were
added to the DCs at a ratio of 1 : 5 (DC : T cell). Proliferative
responses were determined by adding 1 𝜇Ci [0.037MBq]/well
of tritiated thymidine (3H) (MPBiomedicals) to the cells after
three days of coculture. 3H incorporation over a time course
of 16 hours was measured with a scintillation counter.
2.4. Cocultures of DCs with Naive CD4+ T Cells and Analysis
of the CD4+ T Cell Phenotype. Dendritic cells (1 × 104) were
stimulated overnight with the different stimuli in 100 𝜇L
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Figure 1: Phenotype of human blood DCs upon TLR stimulation. (a) MHC class I (HLA-ABC) and MHC class II (HLA-DR) expression
was analyzed by flow cytometry of DCs kept at 4∘C or DCs stimulated and cultured overnight. Myeloid DCs were stimulated with R848 and
polyI:C (pI:C), whereas pDCs were stimulated with R848 alone. The bar graphs show the mean ± SEM of the mean fluorescent intensity
(MFI) (𝑛 ≥ 3) and the histogram shows expression of freshly isolated DC subsets from a single representative donor (filled histogram: isotype
control; grey line: pDCs, black line: CD1c+mDCs, dashed line: CD141+mDCs). (b)The bar graphs (upper panel) show the fold change ± SEM
of the MFI for surface expression of the costimulatory molecules CD80 and CD86 after overnight stimulation with reference to cells cultured
in medium alone (or IL-3 for pDCs) (𝑛 ≥ 4). The histograms (lower panel) show CD80 and CD86 expression from a single representative
donor (insets: MFI values). Significance was determined by Kruskal-Wallis test followed by Dunn’s testing comparing different conditions of
the same subset (∗𝑃 < .05; ∗∗𝑃 < .01; ∗∗∗𝑃 < .001).
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Figure 2: TLR ligation induces differential cytokine production
by human blood DCs. The DCs were stimulated as indicated and
cultured overnight at 37∘C. IL-10 and IL-12p70 production was
analyzed in supernatants of overnight cultures by standard sandwich
ELISA (𝑛 ≥ 6). Each symbol represents one donor (also across
the subsets). Significance was determined by Kruskal-Wallis test
followed by Dunn’s testing comparing different conditions of the
same subset ( ∗∗𝑃 < .01; ∗∗∗𝑃 < .001).
medium. Next, allogeneic naive CD4+ T cells (4 × 104) were
added at a ratio of 1 : 4 (DC : T cell) in a final volume of
200𝜇L medium containing 10 pg/mL superantigen Staphylo-
coccus aureus enterotoxin B (SEB) (Sigma). At day 5, human
rIL-2 (20 IU/mL, Novartis) was added and the cultures
expanded for the next 6–8 days. On days 11–13, resting T
cells were counted and analyzed by flow cytometry with three
panels. Panel 1 includes anti-CD25-APC (BD Bioscience),
anti-CD127-PE (eBioscience), and anti-Foxp3-A488 (eBio-
science). Panel 2 includes anti-T-bet-A488, anti-GATA-3-PE,
and anti-ROR𝛾t-APC (all eBioscience). Panel 3 includes anti-
CD45RO-APC (BD Bioscience), anti-CD197 (R&D Systems)
with goat-anti-mouse IgG2a-A488 (Life Technologies), and
anti-CD62-L (eBioscience) with rat-anti-mouse IgG1-PE (BD
Pharmingen). The population of Tregs was determined by
selecting CD25+ CD127− cells and subsequently gating on the
FoxP3+ population (Suppl. Fig. 2a). From CD45RO+ cells,
TCM were determined by further gating on CD197
+/CD62-
L+ and TEM were determined by further gating on CD197
−
cells. Both populations are shown as percentage of live cells
(forward-sideward scatter) (Suppl. Fig. 2b).
Furthermore, 5 × 104 of the T cells of each condition
were restimulated with 5 × 104 anti-CD3/anti-CD28 beads
(Dynabeads Gibco by Life Technologies) in triplicate and
supernatants from 24-hour cultures were analyzed for levels
of IFN-𝛾 (Pierce Endogen), IL-5, and IL-10 (eBioscience) by
standard sandwich ELISA.
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Figure 3: Human blood DCs induce proliferation of naive CD4+ T
cells. HumanCD1c+mDCs, CD141+mDCs, and pDCswere cultured
overnight with the stimuli as indicated. The next day, allogeneic
naive CD4+ T cells were added to the DCs (ratio 5 : 1). Proliferation
was measured at day four of coculture by determining tritiated
thymidine incorporation. The graph shows the mean proliferation
± SEM in counts per minute [cpm] (𝑛 ≥ 4). Each experiment
was performed in triplicate for CD1c+ mDCs and pDCs and in
duplicate for CD141+ mDCs. Significance was tested for each subset
in comparison with T cells alone by Kruskal-Wallis test followed by
Dunn’s testing (∗𝑃 < .05; ∗∗𝑃 < .01; ∗∗∗𝑃 < .001).
2.5. Statistical Analysis. Data were analyzed by Kruskal-
Wallis test followed by Dunn’s testing, by a 1-way ANOVA
followed by Tukey testing or with paired Student’s 𝑡-test
using Prism5 (GraphPad Prism5). Statistical significance was
defined as <0.05 (∗𝑃 < .05; ∗∗𝑃 < .01; ∗∗∗𝑃 < .001).
3. Results
3.1. TLR Ligation Increases Expression of Costimulatory
Molecules by Human Blood DCs. High expression of MHC
molecules is a hallmark of DCs, underlining their antigen-
presenting capacities. Accordingly, we found high levels of
both MHC class I and MHC class II molecules on all three
DC subsets (Figure 1(a)). The levels of both MHC class I
and MHC class II molecules were highest for CD141+ mDCs
and comparable for CD1c+ mDCs and pDCs, both on freshly
isolated cells and after TLR activation.
The expression of costimulatory molecules by DCs is
essential to activate T cells and can be induced by TLR
ligands. Throughout the study, CD1c+ and CD141+ mDC
maturation was achieved by polyI:C, R848, or a combination
of both. CD1c+mDCswere also stimulated with granulocyte-
macrophage colony-stimulating factor (GM-CSF). Plasmacy-
toid DCs were stimulated with R848 or CpG and IL-3 used
for the control to secure pDC survival. On CD1c+ mDCs, the
costimulatory molecule CD86 was already highly expressed
after overnight culture in medium alone; on CD141+ mDCs,
this holds true for the expression of both CD80 and CD86
(Figure 1(b)). In comparison, CD141+ mDCs showed the
highest expression of CD80 andCD86, both after culturing in
medium alone or after TLR ligation (Figure 1(b)). Although
CD80 and CD86 molecules were expressed already at high
levels on immature DCs, expression of both molecules was
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Figure 4: Mature human DC subsets can skew naive CD4+ T cells towards Th1 phenotype and do not induce a big population of Tregs.
Human blood DCs were incubated with the indicated stimuli. The next day, allogeneic naive CD4+ T cells were added to the DCs together
with a low concentration of the superantigen SEB (10 pg/mL) and cultured until resting (11–13 days). (a) These CD4+ T cells were analyzed
by flow cytometry for presence of a Treg population (CD25+CD127−FoxP3+ CD4+ T cells) (𝑛 ≥ 5). (b) The cells were also stained for the
expression of transcription factors T-bet, Gata-3, and ROR𝛾t. In the lower panel, all three transcription factors are depicted in a single bar
graph (mean value for each). (c) Furthermore, 5 × 104 of these CD4+ T cells were restimulated for 24 hrs with anti-CD3/anti-CD28 beads.
Supernatants were analyzed for IL-5, IL-10, and IFN-𝛾 by sandwich ELISA (𝑛 ≥ 4). The bar graphs show mean cytokine production ± SEM.
In the lower panel, all three cytokines are depicted in a single bar graph (mean value for each cytokine). Significance comparing different
conditions of the same subset was determined by Kruskal-Wallis test followed by Dunn’s testing (a and c), by a 1-way ANOVA followed by
Tukey testing or a paired 𝑡-test (b) (∗𝑃 < .05; ∗∗𝑃 < .01).
significantly increased upon culture with TLR ligands on all
DCs.
3.2. TLR Ligation Induces Differential Cytokine Production by
Human Blood DCs. Dendritic cell-derived IL-10 is known to
inhibitTh1 cells and induce type 1 Tregs (Tregs producing IL-
10), whereas IL-12 is a Th1-inducing cytokine and therefore
desirable in the context of anticancer therapy [20, 21]. We
directly compared the secretion of these cytokines by the
differentially stimulated DC subsets. Plasmacytoid DCs did
not secrete IL-10 or IL-12 at detectable levels, whereas CD1c+
and CD141+ mDCs secreted both IL-10 and IL-12 at differ-
ential levels depending on the stimulus (Figure 2). R848 and
polyI:C, alone or in combination, induced IL-10 production
in CD1c+ mDCs, while only the combination of both TLR
ligands induced a significant increase in the secretion of IL-
12. CD141+mDCs secreted low amounts of IL-10, irrespective
of the stimulus and at lower levels than CD1c+ mDCs. We
observed a significant increase in IL-12 production byCD141+
mDCs after stimulation with both polyI:C and R848, which
is higher than the production by CD1c+ mDCs. We can
therefore conclude that CD141+mDCs produce less IL-10 and
more IL-12 than CD1c+ mDCs.
3.3. Human Blood DCs Induce Proliferation of Allogeneic
Naive CD4+ TCells. Aprimary immune response constitutes
the activation of naive T cells in response to antigen and
their subsequent proliferation and differentiation. Besides
recognition of their cognate antigen, naive T cells depend
on costimulation by the antigen-presenting cell to start such
a primary response. The ability of blood DCs to induce
proliferation of naive T cells was directly compared by cocul-
turing overnight stimulated pDCs and CD1c+ and CD141+
mDCs of the same donors with allogeneic naive CD4+ T cells.
Proliferation was measured at day four by tritiated thymidine
incorporation. All primary blood DC subsets showed the
ability to induce proliferation of naiveCD4+ Tcells (Figure 3).
Even so, R848-matured mDCs induced the highest levels
of proliferation, while polyI:C maturation did not further
increase proliferation as compared to unstimulated mDCs.
For pDCs, R848 and IL-3 (control) treatment stimulate sim-
ilar levels of naive CD4+ T cell proliferation, while the levels
for CpG-treated pDCs tend to be lower than for R848 or IL-3.
Besides providing effector T cells, a primary immune
response can generate immunological memory in the form
of memory T cells. While central memory T cells (TCM)
are responsible for rapid clonal expansion after reexposure
to antigen and localize in lymphoid organs, effector mem-
ory T cells (TEM) localize in mucosal tissue and mediate
rapid effector functions there. Although the formation and
longevity of such memory cells can only be accurately
measured in vivo, we wanted to get an idea of the individual
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capacities of the different DC subsets to induce them. For
this, we cocultured naive, allogeneic CD4+ T cells with the
differentially activated blood DC subsets until the T cells had
ceased to proliferate [27]. At this resting state (after ∼12 days),
we analyzed their CD45RO, CCR7 (CD197), and L-selectin
(CD62L) expression. The percentages of CD45RO+ CCR7−
(TEM) and CD45RO
+ L-selectin+ CCR7+ (TCM) among the
T cells did not differ significantly between the subsets or
different stimuli (Suppl. Fig. 3 and 2b). At the time point
measured, the T cells comprise a larger proportion of TEM
(mean 47.14%–71.51%) than TCM (mean 13.47%–24%).
Taken together, all subsets can effectively induce pro-
liferation of naive T cells and are probably able to induce
memory T cells. However, mDCs induce significantly higher
proliferation when matured with R848 in comparison to
polyI:C maturation or culturing alone.
3.4. All Human Blood DCs Can Drive IFN-𝛾 Production by
Naive CD4+ T Cells and Do Not Induce Tregs. Dendritic cells
play a critical role in the polarization of naive CD4+ T cells
into different T helper phenotypes or Tregs. In aTh1 response,
cytotoxic CD8+ T cells that are able to kill cells bearing their
specific antigen are elicited. Therefore, this type of immune
response is highly desirable in antitumor strategies. To
compare the differential T cell stimulatory and polarizing
capacity—especially the capacity to induce Th1 responses
upon differential stimulation with polyI:C, R848, and CpG—
and possible Treg induction by human blood mDCs and
pDCs, naive CD4+ T cells were cocultured with the DC
subsets until they reached resting state. Importantly, analysis
of the resting T cells did not show a large fraction of Tregs
for any DC subset or condition (mean 3%–10%) (Figure 4(a);
Suppl. Fig. 2a). Although the differences are small, it is
interesting to note that the percentages of these cells were
lowest for polyI:C and R848-matured mDCs and were
highest for GM-CSF-stimulated CD1c+ mDCs (mean 3%
and 10%, resp.). For the pDC cocultures, there is a tendency
of a higher proportion of Tregs being induced after R848 or
CpG stimulation compared to the control (IL-3-treated cells)
(mean 7%, 7%, and 4%, resp.). Furthermore, we analyzed the
induction ofTh subset-specifying transcription factors T-bet,
GATA-3, and ROR𝛾t (Figure 4(b)). We found pronounced
populations expressing T-bet across the subsets and stimuli
(CD1c+ mDCs: 9%–35%, CD141+ mDCs: 23%–35%, and
pDCs: 32%–42%), indicating Th1 polarization by all subsets.
GATA-3 expression was overall low, indicating little Th2
polarization. CD141+ mDCs showed the most pronounced
GATA-3 expression for control and R848 stimulation (mean
5.1% and 4.25%, resp.), which was significantly reduced
with polyI:C or combined R848 and polyI:C stimulation of
CD141+ mDCs (mean 1.87% for both). Furthermore, ROR𝛾t
expression was only detected in a very small population of
CD4+ T cells across the subsets (0.08%–0.72%), indicating
Th1 rather thanTh17 polarization of these cells.
Resting CD4+ T cells were also restimulated with anti-
CD3/anti-CD28 beads and their supernatants analyzed for
IL-5, IL-10, IL-17, and IFN-𝛾 production to determine the
Th1 polarization capacity of the DC subsets. Interleukin-5 is
a Th2 cytokine, while IL-10 inhibitsTh1polarization and IFN-
𝛾 is a strongTh1 inducer [20, 21, 28]. Notably, coculture with
all three blood DC subsets induced T cells with prominent
IFN-𝛾 production after restimulation even without TLR
maturation (Figure 4(c)). T cells primed by CD141+ or CD1c+
mDCs induced prominent populations of T-bet expressing
cells and secreted high levels of IFN-𝛾, indicatingTh1 skewing
(Figure 4(c), lower panel). GM-CSF-stimulatedCD1c+mDCs
induced smaller populations of T-bet expressing cells and
lower levels of IFN-𝛾 and similar levels of both IL-5 and IL-
10 as the medium control or TLR-matured DCs; therefore,
GM-CSF maturation of CD1c+ mDCs does not induce the
most potent Th1 response. Also pDCs induce a prominent
population of T-bet expressing cells and IFN-𝛾 release from
restimulated CD4+ T cells, although the levels of IFN-𝛾 are
lower than for optimally stimulated mDCs. Plasmacytoid
DCs induce similar levels of IL-5 in cocultured T cells as
mDCs. However, the levels of IL-10 are higher, especially
for R848 and CpG stimulated pDCs, which coincides with a
tendency for a bigger proportion of Tregs (CD25+ CD127−
FoxP3+) induced in these conditions. We measured no IL-17
for pDCs and modest levels for mDCs stimulated with R848
or CD1c+ mDCs stimulated with the combination of R848
and polyI:C (Suppl. Fig. 4). Together with the ROR𝛾t expres-
sion data we conclude a Th1 rather than Th17 polarization
of the na¨ıve CD4+ T cells. In sum, all subsets polarize naive
CD4+ T cells mainly towards Th1 cells with a strong T-bet
signature producing mainly IFN-𝛾 after restimulation.
4. Discussion
In order to manipulate T cell responses for DC-based cancer
immunotherapy, a better understanding of the functional
specialization of human DC subsets is needed. In this study,
we compared the capacities of primary human blood mDCs
and pDCs to activate and polarize CD4+ T cells side by side.
We report that CD1c+ mDCs, CD141+ mDCs, and pDCs all
induce proliferation of naive CD4+ T cells. Importantly, naive
CD4+ T cells are not skewed towards a regulatory phenotype
by coculture with either mature mDCs or pDCs. Despite dif-
ferences in activation and cytokine profile, both CD141+ and
CD1c+mDCspolarize naiveCD4+ Tcells towardsT cells with
a strong IFN-𝛾 signature; also pDCs induce IFN-𝛾, although
at lower levels and accompanied by a higher IL-10 production.
While all DC subsets mature upon TLR ligation, we
observed distinct cytokine responses for different subsets and
stimuli. CD1c+ mDCs produced only a limited amount of IL-
12 after maturation with either R848 or polyI:C alone, but
production was significantly increased with a combination of
these TLR ligands. Even higher levels of IL-12 are produced
by CD141+ mDCs when stimulated with the combination of
polyI:C andR848. In contrast to our findings,Nizzoli et al. did
not find IL-12 production for CD141+ mDCs after combined
polyI:C and R848 stimulation [29]. Other studies have shown
that, in order to induce strong IL-12 responses in human
and mouse DCs, both an innate trigger such as TLR ligation
and a second trigger like ligation of CD40 by CD40L on T
cells are needed [7, 30]. More recently, it has been shown for
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CD1c+ mDCs that the combination of the TLR ligands R848
and LPS can trigger significant IL-12 production [29]. In the
case of CD141+ mDCs, a cocktail of polyI:C together with
the cytokines IFN-𝛾, TNF-𝛼, IFN-𝛼, and IL-1𝛽 was shown to
induce significant levels of IL-12 [31]. He´mont et al. showed
thatCD141+mDCsproduced less IL-12 as compared toCD1c+
mDCs for single TLR ligation but that a higher proportion
produced IL-12 after TLR1/2 or TLR3 ligation in a whole
blood assay [7]. Our data supports the notion that a single
stimulus is not sufficient to induce high IL-12 production and
with polyI:C and R848 we describe a new combination that
can trigger substantial IL-12 secretion by both human mDC
subsets.
All DC subsets induced proliferation of naive CD4+
T cells—regardless of the stimulus. The level of T cell
proliferation induced by polyI:C-maturedmDCs is similar to
nonstimulatedmDCs. Strikingly,GM-CSF-stimulatedCD1c+
mDCs and R848-matured CD1c+ and CD141+ mDCs cause
an extra boost in proliferation of naive CD4+ T cells. This
is in accordance with an earlier study by Jongbloed et al.,
which described equally high induction of proliferation of
naive CD4+ T cells for nonstimulated or polyI:C stimulated
CD1c+ and CD141+ mDCs after six days [31]. Because of the
upregulation of the expression of costimulatory molecules
with both stimuli compared to untreated DCs, one would
expect a higher proliferation rate than with untreated DCs.
Certainly, other cytokines and immunostimulatory, but also
immunoinhibitory, molecules expressed by cultured DCs
are integrated into a single response by the T cells and
possible differences in these factors might cause the observed
differences in T cell proliferation.
Only a minor percentage of CD4+ T cells that grew
out of cocultures with the different DC subsets displayed a
Treg phenotype. Earlier studies suggest that pDCs can act
as Th1, Th2, Th17, or even Treg inducers in T cell priming,
depending on the stimulus they receive (summarized in
[9]). One stimulus that can induce this regulatory T cell
phenotype is CpG and the proposed mechanism is via the
expression of inducible costimulator ligand (ICOS-L) [32].
Ito et al. show in their study that pDCs upregulate ICOS-
L upon CpG maturation, which triggers IL-10 production
of T cells but no production of IL-4, IL-5, or IL-13. This is
in accordance with our findings, where we observed higher
levels of IL-10 and a tendency of a higher proportion of Tregs
for pDCs matured with CpG or R848 compared to matured
mDCs but no elevated levels of IL-5. However, regardless of
the stimulus we also found a strong T-bet expression and
IFN-𝛾 production by CD4+ T cells that had grown out of
cocultures. Plasmacytoid DCs secrete large amounts of type I
IFNs in response to bacterial or viral stimuli, including R848
and CpG [8]. Type I IFNs not only are important in innate
responses, but can also help to skew T cells towards a Th1
phenotype [33]. Type I IFNs secreted by pDCs might play a
role in the observed IFN-𝛾 induction.
Regulatory T cell induction with functional effects on T
cells has been described in one study for tissue mDCs of the
skin [34]. We show here that primary blood mDCs induce
only a low proportion of Tregs and, importantly, the overall
CD4+ T cell population displays aTh1 phenotype after cocul-
ture (pronounced T-bet expression and high IFN-𝛾 produc-
tion) and noTh2 orTh17 phenotype. Myeloid DCs induced a
strongTh1 phenotype in CD4+ T cells. This is in line with the
ability of mDCs to produce IL-12 after combined polyI:C and
R848 stimulation. For the other conditions, one can speculate
whether the addition of the CD4+ T cells and therefore
ligation ofCD40on theDCs give the needed second signal for
IL-12 production and help the Th1 skewing. Different groups
have shown that blood mDCs can induce IFN-𝛾 production
in naive CD4+ and CD8+ T cells [7, 35, 36]. Jongbloed et al.
found that CD141+mDCs were more potent than CD1c+ DCs
at inducing IFN-𝛾 responses in total CD4+ T cells, especially
after polyI:C stimulation [31]. We found that although CD1c+
mDCs show a less mature phenotype than CD141+ mDCs
including higher IL-10 and lower IL-12 production, CD1c+
and CD141+ mDCs induce similar IFN-𝛾 responses after
coculture with naive CD4+ T cells. However, there is a
tendency for CD141+mDCs to induce less IL-5 and IL-10 than
CD1c+, also arguing for an overall stronger Th1 skewing by
this subset. For CD141+mDCs, high TLR3 expression and the
ability to produce IFN-𝜆 and CXCL10, both known to induce
antiviral responses, all suggest their capability to induce Th1
skewing in T cells [7, 37, 38]. Certainly, R848 and polyI:C can
trigger distinct pathways as TLR3 signals through a TRIF-to-
IRF3 pathway, rather than anMyD88-to-IRF7 pathway that is
used by TLR8. It is interesting to note that both mDC subsets
react strongly and in a similar way to polyI:C, although the
expression levels of TLR3 are much higher in CD141+ mDCs
than in CD1c+ mDCs [7]. Likely, other receptors for polyI:C
contribute to the response in one or both of themDC subsets.
The synthetic dsRNA analog is a ligand formultiple pathogen
recognition receptors, and besides TLR3 also triggers cytoso-
lic RIG-I-like receptors that are expressed by mDCs [39, 40].
Perrot et al. suggest in a study on mDCs and NK cells that
both TLR3 stimulation and RIG-I-like receptor ligation are
needed for IFN-𝛾 induction by mDCs [41].
In addition to their CD4+ T cell activating capacities,
all three subsets can cross-present exogenous antigens for
cognate restimulation of previously activated CD8+ T cells
[10–14], making them promising candidates for DC-based
vaccination strategies against cancer. Both CD1c+ mDCs and
pDCs have generated promising results in first clinical studies
utilizing these primary blood DC subsets as vaccines [17, 18].
These studies support their excellent in vivo functioning and
mark them as the next generation of cancer vaccines. In this
context, we have learned from the current work that GM-CSF
is not the optimal stimulus for CD1c+ mDCs, since GM-CSF
stimulation showed an overall lower Th1 skewing capacity
and inducedmoreTregs than other stimuli.Whilematuration
with polyI:C or the combination of polyI:C and R848 induces
the most pronouncedTh1 skewing, the number of T cells that
grow out with these stimuli is lower than, for example, with
R848 stimulation. Considering the proliferation data and the
similar polarization capacity by all subsets andwith all stimuli
including control DCs, one can only speculate about a rec-
ommendation for a suited stimulation of DCs for DC-based
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vaccination strategies. However, TLR maturation probably
has extra benefits beyond skewing T cell polarization. For
example, TLR activation of DCs can lead to the upregulation
of otherwise unexpressed TLR ligands in the DCs [42], mak-
ing them sensitive to a broader range of danger signals. Fur-
thermore, in an in vivo situation also other cell types might
play a crucial role for the overall outcome of a therapy. Such
cells include NK and CD8+ T cells, for which type I IFNs and
IL-12—secreted at higher levels upon TLR maturation—are
important [43–46]. As discussed above, CD141+ mDCs cer-
tainly display promising properties for DC-based anticancer
vaccination strategies. Besides their Th1-inducing capacity,
human CD141+ mDCs are also excellent cross-presenters of
exogenous antigens to CD8+ T cells.While some publications
show superior cross-presentation capacity of CD141+ mDCs
[31, 47–49] and put them forward as the human counterparts
of mouse CD8𝛼+ DCs [31, 47–50], other studies suggest
that the different human DCs subsets bear similar cross-
presentation capacities at least for soluble antigens delivered
through early endosomes [14, 15, 51]. The type and size of the
antigen aswell as the compartments they are targeted to prob-
ably underlie these differing outcomes (reviewed in [52, 53]).
In addition to using single subsets for therapeutic approaches,
we hypothesize that using a combination of several DC sub-
sets could further increase T cell activating properties, since
earlier studies have shown that cell-cell interactions as well
as soluble factors can act to cross-activate the different DCs
(summarized in [54]). With this comparative study, we have
reinforced the establishment of human circulating CD1c+
mDCs, CD141+mDCs, and pDCs as promising candidates for
DC-based immunotherapy in the context of cancer.
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